FDA
-
-
-
-
-
-
-
IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer
-
-
-
-
-
-
-
Imunon (IMNN) Announces PlaCCine DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development
-
-
-
-
-
-
-
Imunon (IMNN) Finalizes Phase 3 Study Design with FDA for IMNN-001
-
-
-
-
-
-
-
IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting
-
-
-
-
-
-
-
Imunon (IMNN) Regains Nasdaq Compliance
-
-
-
-
-
-
-
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
-
-
-
-
-
-
-
IMUNON Reports 2022 Financial Results and Provides Business Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

